Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation

Sebagh, Mylène; Radenne, Sylvie; Botta, D.; Silvain, Christine; Lebray, Pascal; Houssel‐Debry, Pauline; Kamar, Nassim; d’Altéroche, Louis; Pageaux, Georges‐Philippe; Duclos‐Vallée, Jean‐Charles; Coilly, Audrey; Bellissant, Éric; Botta‐Fridlund, Danielle; Diallo, Alpha; Dumortier, Jérôme; Durand, François; Duvoux, Christophe; Fougerou‐Leurent, Claire; Leroy, Vincent; Petrov–Sanchez, Ventzislava; Renault, Alain; Rohel, Alexandra; Roque, A.M.; Taburet, Anne‐Marie; Veislinger, Aurélie

doi:10.1016/j.cgh.2015.05.030

Cited by 125 publications

(96 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10,11 Recently, combination of sofosbuvir and daclatasvir or ledipasvir with or without ribavirin has been used in this condition with a 96-100% success rate. [12][13][14] In our series, all patients achieved SVR 12 on 24 weeks treatment of sofosbuvir and ribavirin. We conclude that a combination of sofosbuvir and ribavirin for 24 weeks results in a high cure rate of severe HCV recurrence including FCH after solid organ transplant.…”

Section: Discussionmentioning

confidence: 54%

“…Recent reports suggest successful treatment of FCH with response rates and survival rates of 80-100% with the use of sofosbuvir-based regimens. [10][11][12][13][14] We report 4 cases of acute severe HCV recurrence after transplantation including 3 with FCH (3 after liver transplant and 1 after kidney transplant), and successful treatment of these patients with sofosbuvir and ribavirin.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Early Acute Severe HCV Recurrence After Transplantation: From Universal Mortality to Cure

Wadhawan¹,

Vij

Makki

et al. 2017

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Acute severe recurrence of hepatitis C virus (HCV) after solid organ transplant is associated with high mortality. Pegylated interferon and ribavirin are suboptimal in treatment of this severe form of recurrence. We report 4 cases of acute severe HCV recurrence (within 6 months after transplant), including 3 cases with fibrosing cholestatic hepatitis treated with sofosbuvir and ribavirin. All four patients achieved a rapid suppression of HCV RNA with a normalization of liver function tests within 4 weeks of starting therapy. All patients were HCV RNA negative at 12 weeks after stopping therapy. The combination was found to be safe as anemia was the only adverse effect, which developed in 2 patients (1 patient required blood transfusion, while another managed with erythropoietin). Sofosbuvir and ribavirin appear to be safe and efficacious in treatment of acute severe HCV recurrence after organ transplant. ( J CLIN EXP HEPATOL 2017;7:28-32)

show abstract

Section: Discussionmentioning

confidence: 54%

mentioning

confidence: 99%

Early Acute Severe HCV Recurrence After Transplantation: From Universal Mortality to Cure

Wadhawan¹,

Vij

Makki

et al. 2017

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…37 In a study of 23 FCH patients, 15 patients received sofosbuvir plus daclatasvir and 8 patients received sofosbuvir plus ribavirin. 38 Rapid and dramatic clinical improvement was noted with 24 weeks of therapy without the need for liver retransplantation. Interestingly, although the rapid virologic response rates were low, 96% of the treated patients achieved SVR12.…”

Section: Fibrosing Cholestatic Hepatitismentioning

confidence: 98%

Hepatitis C Virus and Liver Transplantation

Berenguer¹

2014

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a major cause of death from infectious disease and is still the leading indication for liver transplantation in the United States and other Western countries. Alloral, direct-acting antiviral (DAA) therapies have revolutionized the field, with HCV cure rates of more than 90% among treated patients. The safety and tolerability of these DAA agents have expanded the feasibility of HCV treatment even in the challenging pre-and post-liver transplant settings. However, the unique properties of DAA agents and the host profiles in these settings can limit the generalizability of HCV regimens, and prolongation of treatment duration or addition of ribavirin may be required in certain scenarios to optimize treatment outcomes. HCV therapy in the liver transplant setting is not one-size-fits-all; thus, this review summarizes the published data and emphasizes the applicability of currently available DAA therapies in patients with decompensated

show abstract

“…Several IFN-free regimens have become available for daily practice, and most studies have demonstrated high SVR rates and good safety outcomes [3,4]. Some IFN-free regimens have demonstrated favorable safety and high eicacy within clinical trials among dificult-to-treat patients such as patients who have experienced DAA treatment, cirrhosis, chronic kidney disease, Human immunodeiciency virus co-infection, those on opiate agonist therapy, and patients with liver transplant [5][6][7][8][9][10]. However, most clinical trials of IFN-free therapy for chronic hepatitis C have excluded hepatitis B virus (HBV) coinfection.…”

Section: Introductionmentioning

confidence: 99%

Impact of HBV Infection on Outcomes of Direct-Acting Antiviral Therapy of Chronic Hepatitis C

Hayashi¹,

Ishigami²,

Ishizu³

et al. 2017

Update on Hepatitis C

View full text Add to dashboard Cite

Background: Most clinical trials of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection have excluded hepatitis B virus (HBV) coinfection, and litle is known about the efects of DAA on chronic hepatitis C patients with HBV coinfection.Recent studies have reported that DAA therapy for HCV can also cause HBV reactivation in patients with HBV and HCV coinfection. The aim of this study was to assess the efects of DAA on sustained virologic response (SVR) and HBV reactivation in patients with chronic hepatitis C. Methods: Participants comprised 199 chronic hepatitis C patients who received DAA therapy (96 men, 103 women; mean age, 66.7 ± 12.0 years). Results: Twelve patients were coinfected with HCV and HBV. Sixty patients were HBV surface antigen negative but positive for hepatitis B core antibody and/or hepatitis B surface antibody, and one hundred and twenty-seven patients had not been exposed to HBV. Rates of SVR in HBV and HCV coinfected patients, HBV prior infection, and no exposure to HBV were 100, 95, and 97%, respectively. Signiicant diferences were seen between each group. No case showed HBV reactivation. Conclusions: DAA treatments were efective in patients with HBV coinfection or HBV prior infection, as well as HCV monoinfection. As the number of cases was small, we still suggest caution regarding HBV reactivation in HCV and HBV coinfected patients undergoing treatment with DAA.

show abstract

Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation

Abstract: Sofosbuvir therapy with daclatasvir or ribavirin leads to major clinical improvement and high rates of sustained virologic response at week 12 in most patients with recurrence of HCV infection and FCH after liver transplantation. ClinicalTrial.gov no: NCT01944527.

Cited by 125 publications

References 24 publications

Early Acute Severe HCV Recurrence After Transplantation: From Universal Mortality to Cure

Early Acute Severe HCV Recurrence After Transplantation: From Universal Mortality to Cure

Hepatitis C Virus and Liver Transplantation

Impact of HBV Infection on Outcomes of Direct-Acting Antiviral Therapy of Chronic Hepatitis C

Contact Info

Product

Resources

About